MedTrace Logo

Drug-drug Interactions Between DWC202211 and DWC202212 in Healthy Subjects

NCT05699070 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-04-04

No results posted yet for this study

Summary

An open-label phase 1 study to evaluate pharmacokinetic/pharmacodynamic drug-drug interactions and safety/tolerability of DWC202211 and DWC202212 compared to coadministration in healthy

Conditions

  • Drug-drug Interaction

Interventions

DRUG

DWC202211 100mg

DWC202211 for 5 days Aspirin 100mg

DRUG

DWC202212 5mg

DWC202212 for 3 days Rabeprazole 5mg

DRUG

DWC202211 100mg + DWC202212 5mg

DWC202211 + DWC202212 for 5 days Aspirin 100mg, Rabeprazole 5mg

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-15
Primary Completion
2023-04-24
Completion
2023-06-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05699070 on ClinicalTrials.gov